A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 27
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.Drew Rasco, Yifan Zhai, Yufeng Li et al.|Journal of Clinical Oncology|2019Cited by 11
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.Xing Zhang, Yifan Zhai, Xizhi Wen et al.|Journal of Clinical Oncology|2019Cited by 8
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.Xing Zhang, Yifan Zhai, Xizhi Wen et al.|Journal of Clinical Oncology|2020Cited by 7
Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational researchRui‐Hua Xu, Zhiyan Liang, Jing Yang et al.|Signal Transduction and Targeted Therapy|2025Cited by 4